Patient Square Capital Lp Top Holdings and 13F Report (2025) About Patient Square Capital LpInvestment ActivityPatient Square Capital Lp has $241.72 million in total holdings as of March 31, 2025.Patient Square Capital Lp owns shares of 19 different stocks, but just 6 companies or ETFs make up 80% of its holdings.Approximately 10.41% of the portfolio was purchased this quarter.About 8.95% of the portfolio was sold this quarter.This quarter, Patient Square Capital Lp has purchased 20 new stocks and bought additional shares in 12 stocks.Patient Square Capital Lp sold shares of 1 stock and completely divested from 5 stocks this quarter.Largest Holdings Roivant Sciences $125,923,200Insmed $25,194,773Liquidia $22,456,167EyePoint Pharmaceuticals $8,032,315Ocular Therapeutix $6,745,059 Largest New Holdings this Quarter 501575104 - Kymera Therapeutics $3,892,041 Holding09627Y109 - Blueprint Medicines $3,407,635 Holding834203309 - Soleno Therapeutics $1,328,970 Holding92941V308 - VYNE Therapeutics $406,112 Holding Largest Purchases this Quarter Scholar Rock 122,000 shares (about $3.92M)Kymera Therapeutics 142,201 shares (about $3.89M)Blueprint Medicines 38,500 shares (about $3.41M)Ocular Therapeutix 449,280 shares (about $3.29M)Mirum Pharmaceuticals 51,462 shares (about $2.32M) Largest Sales this Quarter Liquidia 337,919 shares (about $4.98M) Sector Allocation Over TimeMap of 500 Largest Holdings ofPatient Square Capital Lp Selling Neutral Buying Latest 13F Holdings and Changes Since Previous Quarterly FilingIssuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSectorROIVRoivant Sciences$125,923,2000.0%12,480,00052.1%MedicalINSMInsmed$25,194,773$1,761,002 ▲7.5%330,25010.4%MedicalLQDALiquidia$22,456,167$4,984,305 ▼-18.2%1,522,4529.3%MedicalEYPTEyePoint Pharmaceuticals$8,032,315$388,321 ▲5.1%1,481,9773.3%MedicalOCULOcular Therapeutix$6,745,059$3,293,223 ▲95.4%920,1992.8%MedicalCGEMCullinan Therapeutics$6,653,2500.0%878,8972.8%MedicalNRIXNurix Therapeutics$5,313,876$11,880 ▲0.2%447,2962.2%MedicalMIRMMirum Pharmaceuticals$5,242,108$2,318,363 ▲79.3%116,3622.2%MedicalELVNEnliven Therapeutics$4,995,532$586,464 ▲13.3%253,8382.1%MedicalSRRKScholar Rock$4,951,100$3,922,300 ▲381.3%154,0002.0%MedicalIRONDisc Medicine$4,120,120$1,320,424 ▲47.2%83,0001.7%MedicalAGIOAgios Pharmaceuticals$4,094,148$527,400 ▲14.8%139,7321.7%MedicalKYMRKymera Therapeutics$3,892,041$3,892,041 ▲New Holding142,2011.6%MedicalPHVSPharvaris$3,854,287$594,920 ▲18.3%245,4961.6%MedicalALLOAllogene Therapeutics$3,457,552$1,282,285 ▲58.9%2,368,1861.4%MedicalBPMCBlueprint Medicines$3,407,635$3,407,635 ▲New Holding38,5001.4%MedicalNTLAIntellia Therapeutics$1,655,073$119,448 ▲7.8%232,7810.7%MedicalSLNOSoleno Therapeutics$1,328,970$1,328,970 ▲New Holding18,6000.5%MedicalVYNEVYNE Therapeutics$406,112$406,112 ▲New Holding257,0330.2%MedicalITCIIntra-Cellular Therapies$0$6,012,605 ▼-100.0%00.0%MedicalGERNGeron$0$4,677,289 ▼-100.0%00.0%MedicalSWTXSpringWorks Therapeutics$0$3,365,040 ▼-100.0%00.0%MedicalARVNArvinas$0$1,660,640 ▼-100.0%00.0%MedicalATXSAstria Therapeutics$0$939,210 ▼-100.0%00.0%MedicalShowing largest 100 holdings. View all holdings. More Institutional Buying and Selling Information SEC Filings and Trading Data SEC Filings 13F Filings Top 13F Buys Top 13F Sells Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
